title: Entacapone and prostate cancer risk in patients with Parkinson's disease.
abstract: BACKGROUND
  The association between Parkinson's disease (PD) and prostate cancer, both common in elderly men, is disputable. In the STRIDE-PD study, prostate cancer developed in 9 patients (3.7%) receiving levodopa/carbidopa with entacapone, a catechol-O-methyltransferase inhibitor, versus 2 cases (0.9%) without entacapone. The current pharmacoepidemiological study aimed to determine whether entacapone increases prostate cancer incidence or mortality in PD patients and whether cumulative exposure affects these rates.
  
  
  METHODS
  We performed a retrospective cohort study using population-wide health care registers with patient-level linkage. Prostate cancer incidence and mortality were modeled by Cox's proportional hazards models.
  
  
  CONCLUSIONS
  Use of entacapone with l-dopa/dopa decarboxylase inhibitor caused no increased risk of prostate cancer incidence (hazard ratio [HR]: 1.05; 95% confidence interval: 0.76-1.44) or mortality (0.93; 0.43-1.98). The HR for cumulative entacapone use of >360 days versus never-use was 0.82 (0.56-1.18) for prostate cancer incidence and 1.27 (0.60-2.72) for prostate cancer mortality.
authors: EPID Research Oy, Espoo, Finland.
authors: Pasi
authors: P
authors: Korhonen
authors: Mikko
authors: M
authors: Kuoppamäki
authors: Tuire
authors: T
authors: Prami
authors: Fabian
authors: F
authors: Hoti
authors: Solomon
authors: S
authors: Christopher
authors: Juha
authors: J
authors: Ellmén
authors: Valtteri
authors: V
authors: Aho
authors: Mikko
authors: M
authors: Vahteristo
authors: Eero
authors: E
authors: Pukkala
authors: Jari
authors: J
authors: Haukka
mesh_terms: D000978:Antiparkinson Agents / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors / Q000009:adverse effects*; D002396:Catechols / Q000009:adverse effects*; D015331:Cohort Studies; D004359:Drug Therapy, Combination; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D009570:Nitriles / Q000009:adverse effects*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000453:epidemiology*; D011471:Prostatic Neoplasms / Q000139:chemically induced* / Q000453:epidemiology*; D012042:Registries; D012306:Risk; D013997:Time Factors
chemical_list: D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D009570:Nitriles; D007980:Levodopa; C071192:entacapone
keywords: entacapone; levodopa; pharmacoepidemiology; prostate cancer